Paediatric drug optimization for malaria: meeting report, 24-26 June 2025

Overview

This report provides a synthesis of the outcomes of the first paediatric drug optimization exercise that was held for Malaria. The PADO for malaria meeting brought together academic researchers, clinical experts, implementing partners and other key stakeholders involved in research and development to reach consensus on the first ever PADO lists for malaria. These contain three key antimalarial agents to be developed in the short term (PADO priority list) and to be monitored in the longer term (PADO watch list), with a clear message on the need to continue investigating long-acting injectables, given their potential role in future malaria management. Additionally, the PADO-malaria access list will support all stakeholders to advocate for greater access to, uptake and roll out of the products included, through multiple activities.